Oliveira Cláudia C, Sluijter Marjolein, Querido Bianca, Ossendorp Ferry, van der Burg Sjoerd H, van Hall Thorbald
Department of Clinical Oncology and Blood Transfusion, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Graduate Program in Areas of Basic and Applied Biology, Porto, Portugal.
Department of Clinical Oncology and Blood Transfusion, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Mol Immunol. 2014 Nov;62(1):129-36. doi: 10.1016/j.molimm.2014.06.006. Epub 2014 Jun 28.
Tumors frequently display defects in the MHC-I antigen processing machinery, such as deficiency of the peptide transporter TAP. Interestingly, the residual peptide repertoire contains neo-antigens which are not presented by processing-proficient cells. We termed these immunogenic peptides TEIPP ('T-cell epitopes associated with impaired peptide processing') and were interested to unravel their TAP-independent processing pathways. With an array of chemical inhibitors we assessed the participation of numerous proteases to TAP-independent peptides and found that the previously described catalytic enzymes signal peptidase and furin contributed in a cell-type and MHC-I allele-specific way. In addition, a dominant role for the proteasome and metallopeptidases was observed. These findings raised the question how these proteasome products get access to MHC-I molecules. A novel TEIPP peptide-epitope that represented this intracellular route revealed that the lysosomal peptide transporter ABCB9 ('TAP-like') was dispensable for its presentation. Interestingly, prevention of endolysosomal vesicle acidification by bafilomycin enhanced the surface display of this TEIPP peptide, suggesting that this proteasome-dependent pathway intersects endolysosomes and that these antigens are merely destroyed there. In conclusion, the proteasome has a surprisingly dominant role in shaping the TAP-independent MHC-I peptide repertoire and some of these antigens might be targeted to the endocytic vesicular pathway.
肿瘤常常在MHC-I抗原加工机制中表现出缺陷,例如肽转运体TAP的缺乏。有趣的是,残余的肽库包含加工能力正常的细胞所不呈递的新抗原。我们将这些免疫原性肽称为TEIPP(“与受损肽加工相关的T细胞表位”),并对揭示其不依赖TAP的加工途径感兴趣。我们使用一系列化学抑制剂评估了多种蛋白酶对不依赖TAP的肽的参与情况,发现先前描述的催化酶信号肽酶和弗林蛋白酶以细胞类型和MHC-I等位基因特异性的方式发挥作用。此外,还观察到蛋白酶体和金属肽酶起主要作用。这些发现提出了一个问题,即这些蛋白酶体产物如何进入MHC-I分子。一种代表这种细胞内途径的新型TEIPP肽表位显示,溶酶体肽转运体ABCB9(“类TAP”)对其呈递并非必需。有趣的是,巴弗洛霉素对溶酶体囊泡酸化的抑制增强了这种TEIPP肽的表面展示,这表明这种依赖蛋白酶体的途径与溶酶体相交,并且这些抗原只是在那里被破坏。总之,蛋白酶体在塑造不依赖TAP的MHC-I肽库中具有惊人的主导作用,并且其中一些抗原可能靶向内吞囊泡途径。